Conversion disorder: "an adverse reaction" to watch out for.
A subject was enrolled in a multicenter, double-blinded clinical trial of ofloxacin-containing multidrug therapy for leprosy by the World Health Organization in 1992 and she developed multiple physical symptoms a few hours after taking the regimen. Physical examination and laboratory work-ups could not support a medical diagnosis and she was eventually dropped from the study. Decoding revealed that she belonged in the control group given the World Health Organization/multiple drug therapy-multibacillary regimen. In the course of treatment, she was diagnosed with conversion disorder and was subsequently treated with an antipsychotic.
Legaspi
Pearl Sherienne C
PS
Department of Dermatology, Jose R. Reyes Memorial Medical Center, Rizal Avenue, Sta. Cruz, Manila, Philippines. ticklemeps03@yahoo.com
Abad Venida
Maria Luisa
ML
D000328:Adult; D000928:Antidepressive Agents / Q000008:administration & dosage*; D003291:Conversion Disorder / Q000139:chemically induced* / Q000188:drug therapy*; D024901:Drug Resistance, Multiple, Bacterial; D005260:Female; D006801:Humans; D007917:Leprostatic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D007918:Leprosy / Q000188:drug therapy; D016896:Treatment Outcome
D000928:Antidepressive Agents; D007917:Leprostatic Agents